Download regulatory_inference_sample.csv from Delower/herg-extratrees-deployment: direct link, hf CLI and curl.
- Browser
- Download file 13.7 kB
-
https://huggingface.co/Delower/herg-extratrees-deployment/resolve/main/regulatory_inference_sample.csv
- Command line
-
hf download hf://Delower/herg-extratrees-deployment/regulatory_inference_sample.csv
-
curl -L -o regulatory_inference_sample.csv https://huggingface.co/Delower/herg-extratrees-deployment/resolve/main/regulatory_inference_sample.csv
13.7 kB
| drug,sponsor,stage_reached,status,smiles_canonical,compound_key,ic50_nM,pIC50,ic50_assay_note,ic50_source,blocker_call_10uM,attribution_grade,reason_summary,source_1,source_2,in_training_pool,tier,notes,cls_scaffold_pred,reg_scaffold_pred,note | |
| Almokalant,Astra-Hässle AB (Astra),Phase III,discontinued,CCC[S+]([O-])CCCN(CC)CC(O)COc1ccc(C#N)cc1,ZMHOBBKJBYLXFR,35.36,7.4515,"Project quantitative master median of 4 measurements (ChEMBL CHEMBL240 + BindingDB Q12809 pulls), all ChEMBL assay type B (radioligand displacement on hERG). Per-source medians agree (pIC50 7.452 both) but individual values span 5-250 nM (spread 1.70 log, spread-flagged in the master).",data/herg_master_quantitative.csv (this project; sources ChEMBL CHEMBL362103 + BindingDB),1.0,A,Development programme produced repeated torsades de pointes in patients (4/100 in the pivotal chronic-AF conversion study; 8 patients across 7 studies programme-wide); clinical investigation abandoned.,"Houltz B et al., Cardiovasc Drugs Ther 1999;13:329-338 (primary, Astra-Hässle authors): 'Four patients developed torsades de pointes' among 100 chronic AF patients; Svernhage E et al. 1998: 'During the clinical development program for almokalant... a total of eight patients in seven different studies developed one or more torsades de pointes.'","'New Antiarrhythmic Drugs' (textbook chapter, ScienceDirect): 'The intravenous preparation has been associated with a high incidence of Torsades de Pointes... Clinical investigation is not currently planned.' TTD/DrugMAP lists almokalant as 'Discontinued in Phase 3' for cardiac arrhythmias.",False,1,Selective IKr (hERG) blocker (Astra code H 234/09). Member of external hERG-70 set and of UnihERG_DB; NOT in the locked training pools. IC50 spread across assays is wide (>=1 log flag) - treat the point value cautiously.,1.0,7.451499999999967,IN-SAMPLE demonstration only - all REGFAIL compounds were absorbed into the deployment training files; NOT validation | |
| AZD1305,AstraZeneca,Phase II,discontinued,CC(C)(C)OC(=O)NCCN1C[C@@H]2CN(CCOc3ccc(C#N)cc3F)C[C@H](C1)O2,BLLNYXOLLAVTRF,370.0,6.4318,"hERG IC50 0.37 uM from AstraZeneca's in vitro hERG assay programme, as published (fixed/estimated) in the AZD1305 PK-PD (hERG-JT interval) analysis. Mixed ion-channel blocker (hERG, Nav1.5, Cav1.2); the hERG value is the torsadogenic-relevant one.","Janzén DLI et al., Front Physiol 2016;7:590: 'The estimated IC50 of hERG was 0.37 +/- 0.04 uM.' Not present in this project's ChEMBL/BindingDB pulls.",1.0,A,Phase II AF cardioversion trial: two patients developed torsade de pointes with dose-dependent QTcF prolongation; benefit-risk judged unfavourable and the development programme was discontinued.,"Rónaszéki A et al., Europace 2011;13:1148-1156 (primary Phase II paper): 'Two patients experienced torsade de pointes (TdP)... AZD1305 was effective in converting AF to SR, but was associated with QT prolongation and TdP. The benefit-risk profile was judged as unfavourable and the AZD1305 development programme was discontinued.'","Bergenholm L et al., Br J Pharmacol 2017;174:3268-3283 (AstraZeneca authors): 'AZD1305 is a mixed ion channel blocker (hERG, hNav1.5 and rCav1.2) previously in development for the treatment of atrial fibrillations, which was discontinued due to safety concerns regarding QTc prolongations and TdP risk (Rónaszéki et al., 2011).'",False,1,"Cleanest compound in this set: absent from the locked training pools, from ALL existing held-out sets, and from UnihERG_DB (so also unseen by the incumbent hERG-LTN). Successor to AZD7009 (see report - AZD7009 itself was discontinued for extra-cardiac flu-like symptoms and is excluded).",1.0,6.43180000000002,IN-SAMPLE demonstration only - all REGFAIL compounds were absorbed into the deployment training files; NOT validation | |
| Vanoxerine,Laguna Pharmaceuticals,Phase III,discontinued,Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1,NAUWTFJOPJWYOT,470.0,6.3279,"Project quantitative master median of 2 measurements (ChEMBL CHEMBL240 + BindingDB Q12809), assay type B (hERG binding/displacement family); sources agree exactly (spread 0.0). Functional IKr potency of the same order is reported in the primary electrophysiology literature (Lacerda et al. 2010).",data/herg_master_quantitative.csv (this project; ChEMBL CHEMBL281594 + BindingDB),1.0,A,"Phase III RESTORE SR trial terminated prematurely after 3/26 vanoxerine patients (11.5%, all with structural heart disease) developed torsades de pointes; sponsor wound down and the AF programme ended. (An earlier cocaine-dependence programme had also been stopped over QTc effects.)","Piccini JP et al., Heart Rhythm 2016;13:1777-1783 (RESTORE SR primary report): 'The study was terminated prematurely because of safety concerns... The primary safety end point (all-cause death, ventricular fibrillation/tachycardia requiring intervention, or torsades de pointes) occurred in no patient in the placebo arm vs 11.5% (3 of 26) in the vanoxerine arm. All 3 patients had torsades de pointes and underlying SHD.'","Frontiers in Pharmacology 2020 review of AF antiarrhythmics: 'the study was terminated early due to the occurrence of ventricular arrhythmias and torsades de pointes in the treatment group (Piccini et al., 2016)'; Healio 2016 quoting Piccini: 'The QT prolongation observed with vanoxerine led to a significant risk [for torsades de pointes]'.",False,1,"GBR-12909; multichannel blocker (IKr > ICaL, INa) originally a dopamine-reuptake inhibitor. Member of external hERG-70 set and of UnihERG_DB; NOT in the locked training pools.",1.0,6.3279,IN-SAMPLE demonstration only - all REGFAIL compounds were absorbed into the deployment training files; NOT validation | |
| d-Sotalol,Bristol-Myers Squibb,Phase III,discontinued,CC(C)NC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1,ZBMZVLHSJCTVON,,,"ic50_available=False for functional IC50: no functional hERG IC50 exists in this project's data (the FDA panel row for sotalol is likewise Ki-headline). Binding Ki = 24,663 nM (pKi 4.608), [3H]dofetilide displacement, Negami et al. 2019 SI Table S1 - Ki is recorded here for context only and is NOT pooled as an IC50, per project rules. Qualitative evidence: selective IKr blocker; SWORD dosing was QTc-gated (held above QTc 560 ms).","Ki: data/fda_benchmark_herg.csv, Sotalol row (Negami et al. 2019, Sci Rep 9, SI Table S1; primary Diaz et al. 2004)",,A,"SWORD, the Phase III mortality trial of this selective IKr blocker in post-MI LV dysfunction, was stopped early: mortality 5.0% on d-sotalol vs 3.1% on placebo (RR 1.65), with presumed arrhythmic deaths (RR 1.77) accounting for the excess; standalone d-sotalol development ended (the racemate remains marketed).","Waldo AL et al. (SWORD Investigators), Lancet 1996;348:7-12 (primary): trial stopped after 3,121 of 6,400 planned patients; 'presumed arrhythmic deaths accounted for the increased mortality' on d-sotalol.","Pratt CM et al., Am J Cardiol 1998 - recorded as a caveat, not a contradiction of the termination reason: 'very little objective data supports torsades de pointes or any specific proarrhythmic mechanism' for the individual excess deaths. The Frontiers AF review describes d-sotalol as 'a phase 3 K+ channel (hERG/IKr) blocker' with QTc-gated dosing.",False,1,"IDENTITY OVERLAP: connectivity block is identical to racemic sotalol, which already sits in the FDA panel (approved_blocker) and in hERG-70 - so this row adds a new development HISTORY but not a new chemical identity versus those sets. NOT in the locked training pools (panel lockout); IS in UnihERG_DB. Enantiomer-specific row: SMILES shown is the (R)-(+)-enantiomer (dextrosotalol, PubChem CID 119259); racemate shares the compound_key. Grade A refers to proarrhythmic (hERG-mechanism) mortality as the termination cause; the TdP-specific mechanism for individual deaths is presumed, per the Pratt caveat.",0.0033333333333333335,4.1311208009983424,IN-SAMPLE demonstration only - all REGFAIL compounds were absorbed into the deployment training files; NOT validation | |
| Tedisamil,Solvay Pharmaceuticals,Phase III (NDA filed; FDA advisory review),refused,C1CCC2(C1)C1CN(CC3CC3)CC2CN(CC2CC2)C1,CTIRHWCPXYGDGF,2500.0,5.6021,"Project quantitative master: single functional (ChEMBL assay type F) IC50 measurement, 2,500 nM.",data/herg_master_quantitative.csv (this project; ChEMBL CHEMBL113461),1.0,B,"FDA Cardiovascular & Renal Drugs Advisory Committee (Dec 2007) voted not to recommend approval: the programme showed a narrow therapeutic window with 11 documented torsade-like arrhythmia episodes (5 in men, 6 in women, several requiring cardioversion) and dose-related QT prolongation; Solvay was asked for more data, never resubmitted, and the programme ended.",Circulation 2009 review of new AF drugs / advisory proceedings: tedisamil had 'a narrow therapeutic window'; 'Five torsade-like arrhythmia episodes documented in men and six in women'; the FDA advisory committee 'voted not to recommend approval of tedisamil' and requested Solvay submit more information.,"NCATS Inxight Drugs (tedisamil entry): 'An FDA advisory committee voted against recommending approval of tedisamil maleate in December, 2007.'",False,1,"KC-8857; multichannel class III (IKr/IKs/Ito + INa). Grade B rather than A: the formal regulatory outcome was a non-recommendation + request for more data, with proarrhythmia/QT the central safety issue but not a single-cause refusal letter. Member of external hERG-60 set and of UnihERG_DB; NOT in the locked training pools.",1.0,5.602100000000012,IN-SAMPLE demonstration only - all REGFAIL compounds were absorbed into the deployment training files; NOT validation | |
| Sematilide,Bayer HealthCare (Berlex),Phase III,discontinued,CCN(CC)CCNC(=O)c1ccc(NS(C)(=O)=O)cc1,KHYPYQZQJSBPIX,25000.0,4.6021,"APPROXIMATE literature value: IKr IC50 ~25 uM, whole-cell patch clamp in rabbit atrial myocytes (native IKr, not a hERG expression system), as compiled in vendor technical literature from the primary electrophysiology papers. Sematilide is absent from this project's ChEMBL/BindingDB pulls and masters. The 10 uM blocker call (0) is robust across the reported 10-30 uM range; the point value should be treated as an order-of-magnitude estimate.","Vendor-compiled technical guides (BenchChem, citing the primary sematilide electrophysiology literature): 'Sematilide inhibits this channel in a concentration-dependent manner, with a reported IC50 of approximately 25 uM' (rabbit atrial myocytes).",0.0,C,"Selective IKr blocker discontinued in the cardiac-arrhythmia indication after Phase III-era development; its documented clinical liability was dose-dependent proarrhythmia (aggravation of arrhythmias in 3/14 patients in the clinical pharmacology study; TdP reported). No public source itemizes the sponsor's reason for termination - weakest-evidence member of this set, graded C accordingly.",AdisInsight drug profile (sematilide; originator Bayer HealthCare Pharmaceuticals): Highest Development Phases - 'Discontinued: Cardiac-arrhythmias' (CK-1752 / ZK-110516).,"Synapse (PatSnap) R&D records: 'Drug Highest Phase: Discontinued Phase 3' (Bayer, cardiac arrhythmias); NCATS Inxight Drugs: 'The further development of the drug was discontinued.'",False,1,"Member of external hERG-70 set and of UnihERG_DB; NOT in the locked training pools. Like sotalol, sematilide is a weak-potency hERG blocker whose clinical QT/proarrhythmia liability appeared at high (micromolar) exposure - a deliberately retained hard case for threshold-based calls.",0.0,4.300514999499995,IN-SAMPLE demonstration only - all REGFAIL compounds were absorbed into the deployment training files; NOT validation | |
| Tecastemizole,Sepracor Inc.,Phase III (NDA filed; not-approvable letter),refused,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1,SFOVDSLXFUGAIV,28.0,7.5528,Project quantitative master median of 12 measurements (ChEMBL CHEMBL240 + BindingDB Q12809; assay types B and F; spread 0.01 log - the most precisely measured compound in this set). Potent hERG blocker.,data/herg_master_quantitative.csv (this project; ChEMBL CHEMBL61301 + BindingDB),1.0,C,"FDA issued a not-approvable letter (Mar 2002) for the allergic-rhinitis NDA citing several safety issues - long elimination time/accumulation, phospholipidosis and cardiomyopathy in preclinical studies, and the need for additional data on QTc prolongation; after further studies Sepracor discontinued development (Dec 2003), also weighing antihistamine-market dynamics. QTc was one of several cited reasons - grade C.","BioCentury, 2 Dec 2003 ('Sepracor ends Soltara program'): 'In March 2002, SEPR received a non-approvable letter citing safety issues related to the compound's long elimination time, including phospholipidosis and cardiomyopathy seen in preclinical studies, and the need for additional data on QTc prolongation (a cardiovascular side effect).'","Medscape, 8 Mar 2002 ('FDA rejects allergy drug over side effects'): 'Concerns over cardiac arrhythmias are prompting the US FDA to issue a nonapprovable letter... Tecastemizole also appeared to increase potential for QTc prolongation.' Sepracor SEC Form 424B3 (2004) confirms the Dec 2003 discontinuation decision and its mixed basis.",True,2,"TIER 2: tecastemizole IS present in both locked training pools (it is a common hERG dataset compound) - it must be reported separately and never mixed into Tier-1 scores. It is norastemizole, the active metabolite of astemizole (an FDA-panel drug), but a distinct compound/connectivity. In UnihERG_DB; in no existing held-out set.",1.0,7.552799999999973,IN-SAMPLE demonstration only - all REGFAIL compounds were absorbed into the deployment training files; NOT validation | |